Notice | Nanologica

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2024

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby convened to the extraordinary general meeting on Thursday 22 February 2024, at 12.00 p.m. CET, at Hagberg & Aneborn Fondkommissions’ premises, Jungfrugatan 35, Stockholm. Right to attend the meetingShareholders who wish to participate in the extraordinary general meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Wednesday 14 February 2024, and notify

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2024

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma torsdagen den 22 februari 2024, klockan 12.00, i Hagberg & Aneborn Fondkommissions lokaler, Jungfrugatan 35, Stockholm. Rätt att delta vid stämmanAktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 14 februari 2024, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 16

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

5 April, 2023

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 4 maj 2023, klockan 12.00, i Redeyes lokaler på Mäster Samuelsgatan 42, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: • dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 25 april 2023, • dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den

NOTICE OF THE ANNUAL GENERAL MEETING 2023 NANOLOGICA AB (PUBL)

5 April, 2023

English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday, May 4, 2023, at 12.00 CET, at Redeye's premises at Mäster Samuelsgatan 42, Stockholm. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: •

Nanologica to Execute a Preferential Rights Issue of up to MSEK 94 to Intensify Efforts within Chromatography

23 August, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Nanologica AB (publ) ("Nanologica" or the Company") resolved today, 23 August 2022, to carry out a rights issue of

Kallelse till extra bolagsstämma i Nanologica AB (publ)

23 August, 2022

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma torsdagen den 15 september 2022, klockan 09.00, i Advokatfirman Lindahls lokaler, Nybrogatan 17, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 7 september 2022, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast måndagen den 12 september

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.